An Ecosystem for the Modern R&D Lifecycle
Stop fragmenting your research across disconnected tools. HubMed provides a seamless, AI-assisted digital thread from in-silico compound discovery to audit-proof clinical evaluation. Combining AI-assisted precision with human-in-the-loop oversight, we bridge the 'fragmentation gap' and cut up to 70% of the research-intensive work in every CER.
Solving the Complexity of MedTech, Biotech, and Device R&D
Traditional R&D is bottlenecked by manual molecule screening and an overwhelming "data noise" of scientific literature. HubMed acts as your digital scientific partner, providing a modular architecture that ensures Audit-Proof Data Continuity.
Structured Scientific Rigor
Every insight is powered by the PICO framework, ensuring evidence is traceable, objective, and defensible.
Connected Workflow Continuity
Move from preclinical data straight into your Clinical Evaluation Report (CER) with complete data traceability, zero black-box risk, and full expert control.
Built for Regulatory Scrutiny
Our solutions are designed to meet the strict standards of the 7-Step Notified Body Workflow and EUDAMED requirements.
Medea | Clinical Evaluation & Compliance
AI-assisted clinical evaluation management for medical devices under EU MDR.
Traceable Literature Screening: reduce screening fatigue with systematic, multi-database searching (PubMed, Embase) tethered to raw sources for 100% auditability.
Faster CER Maintenance: move away from stagnant Word/Excel repositories. Centralize evidence appraisal in a secure system that automatically tracks version control and drastically reduces human workflow bottlenecks.
Notified Body & Annex XIV Alignment: standardize clinical evidence reports to systematically eliminate 'Rounds of Questions' (RAQs) with reproducible, fully defensible documentation.
Up to 70% Less Research Time per CER: Slash literature review and appraisal times from an industry average of 42 hours down to 12,6 hours per CER, translating into massive operational cost reductions.
Adam | Preclinical In-Silico Research
Early-stage compound discovery and toxicological safety profiling.
Accelerated Molecule Screening: Rapidly identify bioactive compounds for Nutraceuticals and Cosmetics.
In-Silico Toxicity Prediction: Mitigate formulation failures early by forecasting potential adverse effects and molecular stability before wet-lab testing.
Innovation: Transition from "predicting" to "creating" innovative molecular leads.
The Cost of Non-Compliance
With 75% of Notified Body submissions reported as incomplete, delays are no longer an option. Every month of certification delay costs MedTech companies up to €250K in lost market opportunities, alongside devastating non-compliance penalties. HubMed ensures your lifecycle—from preclinical data to final CER—is audit-ready
Frequently asked questions
Here are some common questions about our solutions.
Yes. HubMed is a modular ecosystem. You can start with Adam for bioactive discovery or deploy Medea to resolve immediate regulatory complexity in your clinical evaluation.
Beyond the 70% time reduction, HubMed provides a clear ROI by mitigating the risk of failed audits, market blocks, and regulatory rework.
Absolutely. We provide dedicated modules for EUDAMED readiness, new supply interruption obligations (MDCG 2024-16), and legacy device transition management through 2029.
Unify Your R&D Today
Move from fragmented documentation to a system that ensures compliance and resolves complexity.